The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Open accessAbstract
Purpose: Evaluate the efficacy of an SN-38-anti-Trop-2 antibody–drug conjugate (ADC) against several human solid tumor types, and to assess its tolerability in mice and monkeys, the latter with tissue cross-reactivity to hRS7 similar to humans. Experimental Design: Two SN-38 derivatives, CL2-SN-38 and CL2A-SN-38, were conjugated to the anti-Trop-2–humanized antibody, hRS7. The immunoconjugates were characterized in vitro for stability, binding, and cytotoxicity. Efficacy was tested in five different human solid tumor-xenograft models that expressed Trop-2 antigen. Toxicity was assessed in mice and in Cynomolgus monkeys. Results: The hRS7 conjugates of the two SN-38 derivatives were equivalent in drug substitution (∼6), cell binding (Kd ∼ 1.2 nmol/L), cytotoxicity (IC50 ∼ 2.2 nmol/L), and serum stability in vitro (t/½ ∼ 20 hours). Exposure of cells to the ADC demonstrated signaling pathways leading to PARP cleavage, but differences versus free SN-38 in p53 and p21 upregulation were noted. Significant antitumor effects were produced by hRS7-SN-38 at nontoxic doses in mice bearing Calu-3 (P ≤ 0.05), Capan-1 (P < 0.018), BxPC-3 (P < 0.005), and COLO 205 tumors (P < 0.033) when compared to nontargeting control ADCs. Mice tolerated a dose of 2 × 12 mg/kg (SN-38 equivalents) with only short-lived elevations in ALT and AST liver enzyme levels. Cynomolgus monkeys infused with 2 × 0.96 mg/kg exhibited only transient decreases in blood counts, although, importantly, the values did not fall below normal ranges. Conclusions: The anti-Trop-2 hRS7-CL2A-SN-38 ADC provides significant and specific antitumor effects against a range of human solid tumor types. It is well tolerated in monkeys, with tissue Trop-2 expression similar to humans, at clinically relevant doses, and warrants clinical investigation. Clin Cancer Res; 17(10); 3157–69. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
García‐Carbonero, R., & Supko, J. G. (2002) · PubMed · Cited by 498
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
Barton, C., Staddon, S., Hughes, C., Hall, P., O'Sullivan, C., Klöppel, G., Theis, B., Russell, R., Neoptolemos, J., & Williamson, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.467 · Cited by 376
Human trophoblast cell-surface antigens defined by monoclonal antibodies.
Lipinski, M., Parks, D. R., Rouse, R. V., & Herzenberg, L. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.5147 · Cited by 306
Koizumi, F., Kitagawa, M., Negishi, T., Onda, T., Matsumoto, S.-I., Hamaguchi, T., & Matsumura, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1605 · Cited by 256
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Fong, D., Moser, P., Krammel, C., Gostner, J. M., Margreiter, R., Mitterer, M., Gastl, G., & Spizzo, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604677 · Cited by 237
Cited by
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Self-citationExploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Metadata
- Authors
- Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M.
- Venue
- Clinical Cancer Research
- Published
- 2011-05-15
- Volume
- 17
- Issue
- 10
- Pages
- 3157-3169
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2099808918
- Cited by
- 311
- References
- 44
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2939
- The paper
- Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011). Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.